Key Insights
The Transthyretin Amyloidosis (ATTR) Treatment Market is experiencing robust growth, projected to reach \$5.30 billion in 2025 and maintain a Compound Annual Growth Rate (CAGR) of 15.40% from 2025 to 2033. This expansion is fueled by several key factors. Firstly, increasing prevalence of ATTR, particularly ATTR-CM (affecting the heart) and ATTR-PN (affecting the nerves), is driving demand for effective therapies. Advancements in diagnostic techniques are leading to earlier and more accurate diagnoses, further contributing to market growth. The market is segmented by disease type (hereditary and wild-type amyloidosis), therapy type (targeted and supportive therapies), and distribution channels (hospitals, retail pharmacies, and others). The development and launch of novel targeted therapies, such as RNAi therapies and other innovative approaches, are significantly impacting the market landscape, offering improved treatment outcomes and contributing to the high CAGR. The strong pipeline of therapies in various stages of clinical development suggests sustained growth throughout the forecast period. Significant investment from pharmaceutical companies, such as Pfizer, Alnylam Pharmaceuticals, and Ionis Pharmaceuticals, reflects the considerable market opportunity.
Transthyretin Amyloidosis Treatment Market Market Size (In Billion)
Geographically, North America currently holds a significant market share, owing to high healthcare expenditure, established healthcare infrastructure, and a greater awareness of ATTR. However, Asia Pacific is expected to witness substantial growth in the coming years, driven by increasing healthcare spending, rising prevalence of the disease, and growing adoption of advanced therapies. Europe will also maintain a substantial market presence. The competitive landscape is characterized by a mix of established pharmaceutical giants and emerging biotech companies, leading to innovation and market competition. The success of new therapies and expansion into emerging markets will continue shaping the market's trajectory over the forecast period. While challenges remain in terms of treatment costs and accessibility, the overall outlook for the ATTR treatment market remains strongly positive.
Transthyretin Amyloidosis Treatment Market Company Market Share
Transthyretin Amyloidosis Treatment Market: A Comprehensive Report (2019-2033)
This insightful report provides a detailed analysis of the Transthyretin Amyloidosis Treatment market, offering a comprehensive overview of its current state and future trajectory. From market sizing and segmentation to competitive landscapes and future growth opportunities, this report is an indispensable resource for stakeholders across the pharmaceutical and healthcare industries. The study period covers 2019-2033, with 2025 as the base and estimated year, and a forecast period of 2025-2033. The historical period analyzed is 2019-2024. The global market is projected to reach xx Million by 2033.
Transthyretin Amyloidosis Treatment Market Market Composition & Trends
This section delves into the intricate structure of the Transthyretin Amyloidosis Treatment market, evaluating key aspects impacting its growth and development. We analyze market concentration, identifying leading players and their respective market shares. The report also examines innovation catalysts, including technological advancements in targeted therapies and supportive care. Regulatory landscapes across key geographical regions are scrutinized, considering their influence on market access and product approvals. Substitute products and their competitive impact are assessed, alongside an in-depth profile of end-users, encompassing healthcare professionals and patients. Finally, we analyze mergers and acquisitions (M&A) activities within the market, evaluating their impact on market dynamics and providing insights into deal values (e.g., xx Million for a significant acquisition in 2023).
- Market Concentration: Highly concentrated, with top 5 players holding approximately xx% market share in 2024.
- Innovation Catalysts: Advancements in RNAi therapies, gene editing, and novel small molecules are driving innovation.
- Regulatory Landscape: Stringent regulatory pathways for orphan drugs impact market entry timelines.
- Substitute Products: Limited effective alternatives currently exist, creating high demand for novel therapies.
- M&A Activity: Significant M&A activity observed in recent years, with deal values totaling xx Million between 2020 and 2024.
Transthyretin Amyloidosis Treatment Market Industry Evolution
This section provides a detailed account of the Transthyretin Amyloidosis Treatment market's evolution, tracing its growth trajectory from 2019 to 2024 and projecting its future course until 2033. We analyze technological advancements, such as the emergence of novel targeted therapies and improved diagnostic tools, and their influence on market expansion. Shifting consumer demands, including increased patient advocacy and growing awareness of transthyretin amyloidosis, are also examined. The report incorporates specific data points, including compound annual growth rates (CAGRs) for different market segments and adoption metrics for newly launched therapies. The market is experiencing significant growth fueled by an increasing understanding of the disease and the development of novel treatment options. The CAGR from 2025 to 2033 is projected to be xx%, driven by factors such as increased diagnostic capabilities, growing patient population, and the launch of new therapies. Market penetration of novel therapies is expected to reach xx% by 2033.
Leading Regions, Countries, or Segments in Transthyretin Amyloidosis Treatment Market
This section identifies the leading regions, countries, and segments within the Transthyretin Amyloidosis Treatment market. The analysis considers market performance across different segments:
By Type:
- ATTR-CM: ATTR-CM segment dominates the market due to its higher prevalence and severity.
- ATTR-PN: ATTR-PN segment shows significant growth potential due to increasing diagnostic capabilities.
By Therapy:
- Targeted Therapy: The targeted therapy segment is witnessing rapid growth driven by the launch of innovative therapies.
- Supportive Therapy: Supportive therapy remains a significant part of the treatment landscape.
By Disease Type:
- Hereditary Amyloidosis: This segment represents a substantial portion of the market.
- Wild-type Amyloidosis: This segment is anticipated to show increasing growth.
By Distribution Channel:
- Hospitals Pharmacy: Hospitals pharmacy is the primary distribution channel due to the specialized nature of treatment.
Key Drivers:
- Increased Investment in R&D: Significant investments in research and development are fueling the discovery and development of novel therapies.
- Strong Regulatory Support: Favorable regulatory policies for orphan drugs are accelerating market entry for new treatments.
Transthyretin Amyloidosis Treatment Market Product Innovations
Recent years have witnessed remarkable advancements in Transthyretin Amyloidosis treatment, marked by the introduction of novel therapies targeting different aspects of the disease pathogenesis. These include RNA interference (RNAi) therapies, small molecule inhibitors, and other targeted therapies. These innovations offer improved efficacy, reduced side effects, and enhanced patient outcomes compared to earlier treatment approaches. Unique selling propositions include improved tolerability profiles, extended treatment durations, and higher efficacy rates. Technological advancements in drug delivery systems are further enhancing treatment accessibility and convenience.
Propelling Factors for Transthyretin Amyloidosis Treatment Market Growth
Several key factors drive the growth of the Transthyretin Amyloidosis Treatment market. Technological advancements, particularly in the development of effective targeted therapies, are paramount. The rising prevalence of transthyretin amyloidosis, coupled with increased diagnostic capabilities, further fuels market expansion. Favorable regulatory landscapes in major markets, along with substantial investment in R&D by pharmaceutical companies, contribute significantly to market growth. Increased patient awareness and advocacy also play a vital role.
Obstacles in the Transthyretin Amyloidosis Treatment Market Market
The Transthyretin Amyloidosis Treatment market faces several challenges. High drug costs and limited insurance coverage create accessibility barriers for patients. Regulatory hurdles and lengthy approval processes can delay the market entry of novel therapies. Competition among established players and emerging biotech companies intensifies market pressure. Supply chain disruptions can also impact treatment availability. The overall impact of these challenges on market growth is estimated to be approximately xx% reduction in the projected market size.
Future Opportunities in Transthyretin Amyloidosis Treatment Market
Future opportunities lie in the development of next-generation therapies with improved efficacy and safety profiles. Expanding into underserved regions and unmet needs will be a major focus. The increasing use of biomarkers for early diagnosis and personalized medicine presents exciting opportunities for the market. Exploring combination therapies and novel drug delivery systems will further enhance treatment outcomes.
Major Players in the Transthyretin Amyloidosis Treatment Market Ecosystem
- Pfizer Inc
- Prothena
- SOM BIOTECH
- Takeda Pharmaceutical Company Limited
- BridgeBio Inc
- Millennium Pharmaceuticals
- Alnylam Pharmaceuticals Inc
- Ionis Pharmaceuticals
- Oncopeptides
- Corino Therapeutics Inc
- Alexion Pharmaceuticals
- Intellia Therapeutics Inc
Key Developments in Transthyretin Amyloidosis Treatment Market Industry
- April 2024: Alexion initiated the Phase 3 DepleTTR-CM clinical study for ALXN2220 to treat ATTR-CM. This signifies significant progress in developing novel therapies for ATTR-CM and could potentially lead to market expansion.
- March 2024: BridgeBio Pharma Inc. partnered with Bayer for the European commercialization of acoramidis for ATTR-CM. This strategic partnership strengthens the market presence of acoramidis and could lead to increased market share for both companies.
Strategic Transthyretin Amyloidosis Treatment Market Market Forecast
The Transthyretin Amyloidosis Treatment market is poised for substantial growth, driven by several key factors. The continued development and launch of innovative therapies, along with a growing understanding of the disease and improved diagnostic tools, will fuel market expansion. Increased investment in R&D and favorable regulatory landscapes will further contribute to market growth. The potential for personalized medicine and combination therapies offers exciting prospects for future advancements in the field, resulting in a substantial market expansion and positive impact on patient care.
Transthyretin Amyloidosis Treatment Market Segmentation
-
1. Type
- 1.1. ATTR-CM (Transthyretin Amyloid Cardiomyopathy)
- 1.2. ATTR-PN (Transthyretin Amyloid Polyneuropathy)
-
2. Therapy
- 2.1. Targeted Therapy
- 2.2. Supportive Therapy
-
3. Disease Type
- 3.1. Hereditary Amyloidosis
- 3.2. Wild-type Amyloidosis
- 3.3. Other Disease Type
-
4. Distribution Channel
- 4.1. Hospitals Pharmacy
- 4.2. Retail Pharmacies
- 4.3. Other Distribution Channel
Transthyretin Amyloidosis Treatment Market Segmentation By Geography
-
1. North America
- 1.1. United States
- 1.2. Canada
- 1.3. Mexico
-
2. Europe
- 2.1. Germany
- 2.2. United Kingdom
- 2.3. France
- 2.4. Italy
- 2.5. Spain
- 2.6. Rest of Europe
-
3. Asia Pacific
- 3.1. China
- 3.2. Japan
- 3.3. India
- 3.4. Australia
- 3.5. South Korea
- 3.6. Rest of Asia Pacific
- 4. Rest of the World
Transthyretin Amyloidosis Treatment Market Regional Market Share
Geographic Coverage of Transthyretin Amyloidosis Treatment Market
Transthyretin Amyloidosis Treatment Market REPORT HIGHLIGHTS
| Aspects | Details |
|---|---|
| Study Period | 2020-2034 |
| Base Year | 2025 |
| Estimated Year | 2026 |
| Forecast Period | 2026-2034 |
| Historical Period | 2020-2025 |
| Growth Rate | CAGR of 15.40% from 2020-2034 |
| Segmentation |
|
Table of Contents
- 1. Introduction
- 1.1. Research Scope
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 1.4. Definitions and Assumptions
- 2. Executive Summary
- 2.1. Introduction
- 3. Market Dynamics
- 3.1. Introduction
- 3.2. Market Drivers
- 3.2.1. Growing Geriatric Population and Risk Factors for Amyloid Light Chain (AL); Increasing Research and Development (R&D) and Growing Disease Awareness
- 3.3. Market Restrains
- 3.3.1. High Cost Associated with the Transthyretin Amyloidosis Treatment
- 3.4. Market Trends
- 3.4.1. The Hereditary Transthyretin Amyloidosis Segment is Expected to Hold a Significant Share Over the Forecast Period
- 4. Market Factor Analysis
- 4.1. Porters Five Forces
- 4.2. Supply/Value Chain
- 4.3. PESTEL analysis
- 4.4. Market Entropy
- 4.5. Patent/Trademark Analysis
- 5. Global Transthyretin Amyloidosis Treatment Market Analysis, Insights and Forecast, 2020-2032
- 5.1. Market Analysis, Insights and Forecast - by Type
- 5.1.1. ATTR-CM (Transthyretin Amyloid Cardiomyopathy)
- 5.1.2. ATTR-PN (Transthyretin Amyloid Polyneuropathy)
- 5.2. Market Analysis, Insights and Forecast - by Therapy
- 5.2.1. Targeted Therapy
- 5.2.2. Supportive Therapy
- 5.3. Market Analysis, Insights and Forecast - by Disease Type
- 5.3.1. Hereditary Amyloidosis
- 5.3.2. Wild-type Amyloidosis
- 5.3.3. Other Disease Type
- 5.4. Market Analysis, Insights and Forecast - by Distribution Channel
- 5.4.1. Hospitals Pharmacy
- 5.4.2. Retail Pharmacies
- 5.4.3. Other Distribution Channel
- 5.5. Market Analysis, Insights and Forecast - by Region
- 5.5.1. North America
- 5.5.2. Europe
- 5.5.3. Asia Pacific
- 5.5.4. Rest of the World
- 5.1. Market Analysis, Insights and Forecast - by Type
- 6. North America Transthyretin Amyloidosis Treatment Market Analysis, Insights and Forecast, 2020-2032
- 6.1. Market Analysis, Insights and Forecast - by Type
- 6.1.1. ATTR-CM (Transthyretin Amyloid Cardiomyopathy)
- 6.1.2. ATTR-PN (Transthyretin Amyloid Polyneuropathy)
- 6.2. Market Analysis, Insights and Forecast - by Therapy
- 6.2.1. Targeted Therapy
- 6.2.2. Supportive Therapy
- 6.3. Market Analysis, Insights and Forecast - by Disease Type
- 6.3.1. Hereditary Amyloidosis
- 6.3.2. Wild-type Amyloidosis
- 6.3.3. Other Disease Type
- 6.4. Market Analysis, Insights and Forecast - by Distribution Channel
- 6.4.1. Hospitals Pharmacy
- 6.4.2. Retail Pharmacies
- 6.4.3. Other Distribution Channel
- 6.1. Market Analysis, Insights and Forecast - by Type
- 7. Europe Transthyretin Amyloidosis Treatment Market Analysis, Insights and Forecast, 2020-2032
- 7.1. Market Analysis, Insights and Forecast - by Type
- 7.1.1. ATTR-CM (Transthyretin Amyloid Cardiomyopathy)
- 7.1.2. ATTR-PN (Transthyretin Amyloid Polyneuropathy)
- 7.2. Market Analysis, Insights and Forecast - by Therapy
- 7.2.1. Targeted Therapy
- 7.2.2. Supportive Therapy
- 7.3. Market Analysis, Insights and Forecast - by Disease Type
- 7.3.1. Hereditary Amyloidosis
- 7.3.2. Wild-type Amyloidosis
- 7.3.3. Other Disease Type
- 7.4. Market Analysis, Insights and Forecast - by Distribution Channel
- 7.4.1. Hospitals Pharmacy
- 7.4.2. Retail Pharmacies
- 7.4.3. Other Distribution Channel
- 7.1. Market Analysis, Insights and Forecast - by Type
- 8. Asia Pacific Transthyretin Amyloidosis Treatment Market Analysis, Insights and Forecast, 2020-2032
- 8.1. Market Analysis, Insights and Forecast - by Type
- 8.1.1. ATTR-CM (Transthyretin Amyloid Cardiomyopathy)
- 8.1.2. ATTR-PN (Transthyretin Amyloid Polyneuropathy)
- 8.2. Market Analysis, Insights and Forecast - by Therapy
- 8.2.1. Targeted Therapy
- 8.2.2. Supportive Therapy
- 8.3. Market Analysis, Insights and Forecast - by Disease Type
- 8.3.1. Hereditary Amyloidosis
- 8.3.2. Wild-type Amyloidosis
- 8.3.3. Other Disease Type
- 8.4. Market Analysis, Insights and Forecast - by Distribution Channel
- 8.4.1. Hospitals Pharmacy
- 8.4.2. Retail Pharmacies
- 8.4.3. Other Distribution Channel
- 8.1. Market Analysis, Insights and Forecast - by Type
- 9. Rest of the World Transthyretin Amyloidosis Treatment Market Analysis, Insights and Forecast, 2020-2032
- 9.1. Market Analysis, Insights and Forecast - by Type
- 9.1.1. ATTR-CM (Transthyretin Amyloid Cardiomyopathy)
- 9.1.2. ATTR-PN (Transthyretin Amyloid Polyneuropathy)
- 9.2. Market Analysis, Insights and Forecast - by Therapy
- 9.2.1. Targeted Therapy
- 9.2.2. Supportive Therapy
- 9.3. Market Analysis, Insights and Forecast - by Disease Type
- 9.3.1. Hereditary Amyloidosis
- 9.3.2. Wild-type Amyloidosis
- 9.3.3. Other Disease Type
- 9.4. Market Analysis, Insights and Forecast - by Distribution Channel
- 9.4.1. Hospitals Pharmacy
- 9.4.2. Retail Pharmacies
- 9.4.3. Other Distribution Channel
- 9.1. Market Analysis, Insights and Forecast - by Type
- 10. Competitive Analysis
- 10.1. Global Market Share Analysis 2025
- 10.2. Company Profiles
- 10.2.1 Pfizer Inc
- 10.2.1.1. Overview
- 10.2.1.2. Products
- 10.2.1.3. SWOT Analysis
- 10.2.1.4. Recent Developments
- 10.2.1.5. Financials (Based on Availability)
- 10.2.2 Prothena
- 10.2.2.1. Overview
- 10.2.2.2. Products
- 10.2.2.3. SWOT Analysis
- 10.2.2.4. Recent Developments
- 10.2.2.5. Financials (Based on Availability)
- 10.2.3 SOM BIOTECH
- 10.2.3.1. Overview
- 10.2.3.2. Products
- 10.2.3.3. SWOT Analysis
- 10.2.3.4. Recent Developments
- 10.2.3.5. Financials (Based on Availability)
- 10.2.4 Takeda Pharmaceutical Company Limited
- 10.2.4.1. Overview
- 10.2.4.2. Products
- 10.2.4.3. SWOT Analysis
- 10.2.4.4. Recent Developments
- 10.2.4.5. Financials (Based on Availability)
- 10.2.5 BridgeBio Inc
- 10.2.5.1. Overview
- 10.2.5.2. Products
- 10.2.5.3. SWOT Analysis
- 10.2.5.4. Recent Developments
- 10.2.5.5. Financials (Based on Availability)
- 10.2.6 Millennium Pharmaceuticals
- 10.2.6.1. Overview
- 10.2.6.2. Products
- 10.2.6.3. SWOT Analysis
- 10.2.6.4. Recent Developments
- 10.2.6.5. Financials (Based on Availability)
- 10.2.7 Alnylam Pharmaceuticals Inc
- 10.2.7.1. Overview
- 10.2.7.2. Products
- 10.2.7.3. SWOT Analysis
- 10.2.7.4. Recent Developments
- 10.2.7.5. Financials (Based on Availability)
- 10.2.8 Ionis Pharmaceuticals
- 10.2.8.1. Overview
- 10.2.8.2. Products
- 10.2.8.3. SWOT Analysis
- 10.2.8.4. Recent Developments
- 10.2.8.5. Financials (Based on Availability)
- 10.2.9 Oncopeptides
- 10.2.9.1. Overview
- 10.2.9.2. Products
- 10.2.9.3. SWOT Analysis
- 10.2.9.4. Recent Developments
- 10.2.9.5. Financials (Based on Availability)
- 10.2.10 Corino Therapeutics Inc
- 10.2.10.1. Overview
- 10.2.10.2. Products
- 10.2.10.3. SWOT Analysis
- 10.2.10.4. Recent Developments
- 10.2.10.5. Financials (Based on Availability)
- 10.2.11 Alexion Pharmaceuticals
- 10.2.11.1. Overview
- 10.2.11.2. Products
- 10.2.11.3. SWOT Analysis
- 10.2.11.4. Recent Developments
- 10.2.11.5. Financials (Based on Availability)
- 10.2.12 Intellia Therapeutics Inc
- 10.2.12.1. Overview
- 10.2.12.2. Products
- 10.2.12.3. SWOT Analysis
- 10.2.12.4. Recent Developments
- 10.2.12.5. Financials (Based on Availability)
- 10.2.1 Pfizer Inc
List of Figures
- Figure 1: Global Transthyretin Amyloidosis Treatment Market Revenue Breakdown (Million, %) by Region 2025 & 2033
- Figure 2: Global Transthyretin Amyloidosis Treatment Market Volume Breakdown (K Unit, %) by Region 2025 & 2033
- Figure 3: North America Transthyretin Amyloidosis Treatment Market Revenue (Million), by Type 2025 & 2033
- Figure 4: North America Transthyretin Amyloidosis Treatment Market Volume (K Unit), by Type 2025 & 2033
- Figure 5: North America Transthyretin Amyloidosis Treatment Market Revenue Share (%), by Type 2025 & 2033
- Figure 6: North America Transthyretin Amyloidosis Treatment Market Volume Share (%), by Type 2025 & 2033
- Figure 7: North America Transthyretin Amyloidosis Treatment Market Revenue (Million), by Therapy 2025 & 2033
- Figure 8: North America Transthyretin Amyloidosis Treatment Market Volume (K Unit), by Therapy 2025 & 2033
- Figure 9: North America Transthyretin Amyloidosis Treatment Market Revenue Share (%), by Therapy 2025 & 2033
- Figure 10: North America Transthyretin Amyloidosis Treatment Market Volume Share (%), by Therapy 2025 & 2033
- Figure 11: North America Transthyretin Amyloidosis Treatment Market Revenue (Million), by Disease Type 2025 & 2033
- Figure 12: North America Transthyretin Amyloidosis Treatment Market Volume (K Unit), by Disease Type 2025 & 2033
- Figure 13: North America Transthyretin Amyloidosis Treatment Market Revenue Share (%), by Disease Type 2025 & 2033
- Figure 14: North America Transthyretin Amyloidosis Treatment Market Volume Share (%), by Disease Type 2025 & 2033
- Figure 15: North America Transthyretin Amyloidosis Treatment Market Revenue (Million), by Distribution Channel 2025 & 2033
- Figure 16: North America Transthyretin Amyloidosis Treatment Market Volume (K Unit), by Distribution Channel 2025 & 2033
- Figure 17: North America Transthyretin Amyloidosis Treatment Market Revenue Share (%), by Distribution Channel 2025 & 2033
- Figure 18: North America Transthyretin Amyloidosis Treatment Market Volume Share (%), by Distribution Channel 2025 & 2033
- Figure 19: North America Transthyretin Amyloidosis Treatment Market Revenue (Million), by Country 2025 & 2033
- Figure 20: North America Transthyretin Amyloidosis Treatment Market Volume (K Unit), by Country 2025 & 2033
- Figure 21: North America Transthyretin Amyloidosis Treatment Market Revenue Share (%), by Country 2025 & 2033
- Figure 22: North America Transthyretin Amyloidosis Treatment Market Volume Share (%), by Country 2025 & 2033
- Figure 23: Europe Transthyretin Amyloidosis Treatment Market Revenue (Million), by Type 2025 & 2033
- Figure 24: Europe Transthyretin Amyloidosis Treatment Market Volume (K Unit), by Type 2025 & 2033
- Figure 25: Europe Transthyretin Amyloidosis Treatment Market Revenue Share (%), by Type 2025 & 2033
- Figure 26: Europe Transthyretin Amyloidosis Treatment Market Volume Share (%), by Type 2025 & 2033
- Figure 27: Europe Transthyretin Amyloidosis Treatment Market Revenue (Million), by Therapy 2025 & 2033
- Figure 28: Europe Transthyretin Amyloidosis Treatment Market Volume (K Unit), by Therapy 2025 & 2033
- Figure 29: Europe Transthyretin Amyloidosis Treatment Market Revenue Share (%), by Therapy 2025 & 2033
- Figure 30: Europe Transthyretin Amyloidosis Treatment Market Volume Share (%), by Therapy 2025 & 2033
- Figure 31: Europe Transthyretin Amyloidosis Treatment Market Revenue (Million), by Disease Type 2025 & 2033
- Figure 32: Europe Transthyretin Amyloidosis Treatment Market Volume (K Unit), by Disease Type 2025 & 2033
- Figure 33: Europe Transthyretin Amyloidosis Treatment Market Revenue Share (%), by Disease Type 2025 & 2033
- Figure 34: Europe Transthyretin Amyloidosis Treatment Market Volume Share (%), by Disease Type 2025 & 2033
- Figure 35: Europe Transthyretin Amyloidosis Treatment Market Revenue (Million), by Distribution Channel 2025 & 2033
- Figure 36: Europe Transthyretin Amyloidosis Treatment Market Volume (K Unit), by Distribution Channel 2025 & 2033
- Figure 37: Europe Transthyretin Amyloidosis Treatment Market Revenue Share (%), by Distribution Channel 2025 & 2033
- Figure 38: Europe Transthyretin Amyloidosis Treatment Market Volume Share (%), by Distribution Channel 2025 & 2033
- Figure 39: Europe Transthyretin Amyloidosis Treatment Market Revenue (Million), by Country 2025 & 2033
- Figure 40: Europe Transthyretin Amyloidosis Treatment Market Volume (K Unit), by Country 2025 & 2033
- Figure 41: Europe Transthyretin Amyloidosis Treatment Market Revenue Share (%), by Country 2025 & 2033
- Figure 42: Europe Transthyretin Amyloidosis Treatment Market Volume Share (%), by Country 2025 & 2033
- Figure 43: Asia Pacific Transthyretin Amyloidosis Treatment Market Revenue (Million), by Type 2025 & 2033
- Figure 44: Asia Pacific Transthyretin Amyloidosis Treatment Market Volume (K Unit), by Type 2025 & 2033
- Figure 45: Asia Pacific Transthyretin Amyloidosis Treatment Market Revenue Share (%), by Type 2025 & 2033
- Figure 46: Asia Pacific Transthyretin Amyloidosis Treatment Market Volume Share (%), by Type 2025 & 2033
- Figure 47: Asia Pacific Transthyretin Amyloidosis Treatment Market Revenue (Million), by Therapy 2025 & 2033
- Figure 48: Asia Pacific Transthyretin Amyloidosis Treatment Market Volume (K Unit), by Therapy 2025 & 2033
- Figure 49: Asia Pacific Transthyretin Amyloidosis Treatment Market Revenue Share (%), by Therapy 2025 & 2033
- Figure 50: Asia Pacific Transthyretin Amyloidosis Treatment Market Volume Share (%), by Therapy 2025 & 2033
- Figure 51: Asia Pacific Transthyretin Amyloidosis Treatment Market Revenue (Million), by Disease Type 2025 & 2033
- Figure 52: Asia Pacific Transthyretin Amyloidosis Treatment Market Volume (K Unit), by Disease Type 2025 & 2033
- Figure 53: Asia Pacific Transthyretin Amyloidosis Treatment Market Revenue Share (%), by Disease Type 2025 & 2033
- Figure 54: Asia Pacific Transthyretin Amyloidosis Treatment Market Volume Share (%), by Disease Type 2025 & 2033
- Figure 55: Asia Pacific Transthyretin Amyloidosis Treatment Market Revenue (Million), by Distribution Channel 2025 & 2033
- Figure 56: Asia Pacific Transthyretin Amyloidosis Treatment Market Volume (K Unit), by Distribution Channel 2025 & 2033
- Figure 57: Asia Pacific Transthyretin Amyloidosis Treatment Market Revenue Share (%), by Distribution Channel 2025 & 2033
- Figure 58: Asia Pacific Transthyretin Amyloidosis Treatment Market Volume Share (%), by Distribution Channel 2025 & 2033
- Figure 59: Asia Pacific Transthyretin Amyloidosis Treatment Market Revenue (Million), by Country 2025 & 2033
- Figure 60: Asia Pacific Transthyretin Amyloidosis Treatment Market Volume (K Unit), by Country 2025 & 2033
- Figure 61: Asia Pacific Transthyretin Amyloidosis Treatment Market Revenue Share (%), by Country 2025 & 2033
- Figure 62: Asia Pacific Transthyretin Amyloidosis Treatment Market Volume Share (%), by Country 2025 & 2033
- Figure 63: Rest of the World Transthyretin Amyloidosis Treatment Market Revenue (Million), by Type 2025 & 2033
- Figure 64: Rest of the World Transthyretin Amyloidosis Treatment Market Volume (K Unit), by Type 2025 & 2033
- Figure 65: Rest of the World Transthyretin Amyloidosis Treatment Market Revenue Share (%), by Type 2025 & 2033
- Figure 66: Rest of the World Transthyretin Amyloidosis Treatment Market Volume Share (%), by Type 2025 & 2033
- Figure 67: Rest of the World Transthyretin Amyloidosis Treatment Market Revenue (Million), by Therapy 2025 & 2033
- Figure 68: Rest of the World Transthyretin Amyloidosis Treatment Market Volume (K Unit), by Therapy 2025 & 2033
- Figure 69: Rest of the World Transthyretin Amyloidosis Treatment Market Revenue Share (%), by Therapy 2025 & 2033
- Figure 70: Rest of the World Transthyretin Amyloidosis Treatment Market Volume Share (%), by Therapy 2025 & 2033
- Figure 71: Rest of the World Transthyretin Amyloidosis Treatment Market Revenue (Million), by Disease Type 2025 & 2033
- Figure 72: Rest of the World Transthyretin Amyloidosis Treatment Market Volume (K Unit), by Disease Type 2025 & 2033
- Figure 73: Rest of the World Transthyretin Amyloidosis Treatment Market Revenue Share (%), by Disease Type 2025 & 2033
- Figure 74: Rest of the World Transthyretin Amyloidosis Treatment Market Volume Share (%), by Disease Type 2025 & 2033
- Figure 75: Rest of the World Transthyretin Amyloidosis Treatment Market Revenue (Million), by Distribution Channel 2025 & 2033
- Figure 76: Rest of the World Transthyretin Amyloidosis Treatment Market Volume (K Unit), by Distribution Channel 2025 & 2033
- Figure 77: Rest of the World Transthyretin Amyloidosis Treatment Market Revenue Share (%), by Distribution Channel 2025 & 2033
- Figure 78: Rest of the World Transthyretin Amyloidosis Treatment Market Volume Share (%), by Distribution Channel 2025 & 2033
- Figure 79: Rest of the World Transthyretin Amyloidosis Treatment Market Revenue (Million), by Country 2025 & 2033
- Figure 80: Rest of the World Transthyretin Amyloidosis Treatment Market Volume (K Unit), by Country 2025 & 2033
- Figure 81: Rest of the World Transthyretin Amyloidosis Treatment Market Revenue Share (%), by Country 2025 & 2033
- Figure 82: Rest of the World Transthyretin Amyloidosis Treatment Market Volume Share (%), by Country 2025 & 2033
List of Tables
- Table 1: Global Transthyretin Amyloidosis Treatment Market Revenue Million Forecast, by Type 2020 & 2033
- Table 2: Global Transthyretin Amyloidosis Treatment Market Volume K Unit Forecast, by Type 2020 & 2033
- Table 3: Global Transthyretin Amyloidosis Treatment Market Revenue Million Forecast, by Therapy 2020 & 2033
- Table 4: Global Transthyretin Amyloidosis Treatment Market Volume K Unit Forecast, by Therapy 2020 & 2033
- Table 5: Global Transthyretin Amyloidosis Treatment Market Revenue Million Forecast, by Disease Type 2020 & 2033
- Table 6: Global Transthyretin Amyloidosis Treatment Market Volume K Unit Forecast, by Disease Type 2020 & 2033
- Table 7: Global Transthyretin Amyloidosis Treatment Market Revenue Million Forecast, by Distribution Channel 2020 & 2033
- Table 8: Global Transthyretin Amyloidosis Treatment Market Volume K Unit Forecast, by Distribution Channel 2020 & 2033
- Table 9: Global Transthyretin Amyloidosis Treatment Market Revenue Million Forecast, by Region 2020 & 2033
- Table 10: Global Transthyretin Amyloidosis Treatment Market Volume K Unit Forecast, by Region 2020 & 2033
- Table 11: Global Transthyretin Amyloidosis Treatment Market Revenue Million Forecast, by Type 2020 & 2033
- Table 12: Global Transthyretin Amyloidosis Treatment Market Volume K Unit Forecast, by Type 2020 & 2033
- Table 13: Global Transthyretin Amyloidosis Treatment Market Revenue Million Forecast, by Therapy 2020 & 2033
- Table 14: Global Transthyretin Amyloidosis Treatment Market Volume K Unit Forecast, by Therapy 2020 & 2033
- Table 15: Global Transthyretin Amyloidosis Treatment Market Revenue Million Forecast, by Disease Type 2020 & 2033
- Table 16: Global Transthyretin Amyloidosis Treatment Market Volume K Unit Forecast, by Disease Type 2020 & 2033
- Table 17: Global Transthyretin Amyloidosis Treatment Market Revenue Million Forecast, by Distribution Channel 2020 & 2033
- Table 18: Global Transthyretin Amyloidosis Treatment Market Volume K Unit Forecast, by Distribution Channel 2020 & 2033
- Table 19: Global Transthyretin Amyloidosis Treatment Market Revenue Million Forecast, by Country 2020 & 2033
- Table 20: Global Transthyretin Amyloidosis Treatment Market Volume K Unit Forecast, by Country 2020 & 2033
- Table 21: United States Transthyretin Amyloidosis Treatment Market Revenue (Million) Forecast, by Application 2020 & 2033
- Table 22: United States Transthyretin Amyloidosis Treatment Market Volume (K Unit) Forecast, by Application 2020 & 2033
- Table 23: Canada Transthyretin Amyloidosis Treatment Market Revenue (Million) Forecast, by Application 2020 & 2033
- Table 24: Canada Transthyretin Amyloidosis Treatment Market Volume (K Unit) Forecast, by Application 2020 & 2033
- Table 25: Mexico Transthyretin Amyloidosis Treatment Market Revenue (Million) Forecast, by Application 2020 & 2033
- Table 26: Mexico Transthyretin Amyloidosis Treatment Market Volume (K Unit) Forecast, by Application 2020 & 2033
- Table 27: Global Transthyretin Amyloidosis Treatment Market Revenue Million Forecast, by Type 2020 & 2033
- Table 28: Global Transthyretin Amyloidosis Treatment Market Volume K Unit Forecast, by Type 2020 & 2033
- Table 29: Global Transthyretin Amyloidosis Treatment Market Revenue Million Forecast, by Therapy 2020 & 2033
- Table 30: Global Transthyretin Amyloidosis Treatment Market Volume K Unit Forecast, by Therapy 2020 & 2033
- Table 31: Global Transthyretin Amyloidosis Treatment Market Revenue Million Forecast, by Disease Type 2020 & 2033
- Table 32: Global Transthyretin Amyloidosis Treatment Market Volume K Unit Forecast, by Disease Type 2020 & 2033
- Table 33: Global Transthyretin Amyloidosis Treatment Market Revenue Million Forecast, by Distribution Channel 2020 & 2033
- Table 34: Global Transthyretin Amyloidosis Treatment Market Volume K Unit Forecast, by Distribution Channel 2020 & 2033
- Table 35: Global Transthyretin Amyloidosis Treatment Market Revenue Million Forecast, by Country 2020 & 2033
- Table 36: Global Transthyretin Amyloidosis Treatment Market Volume K Unit Forecast, by Country 2020 & 2033
- Table 37: Germany Transthyretin Amyloidosis Treatment Market Revenue (Million) Forecast, by Application 2020 & 2033
- Table 38: Germany Transthyretin Amyloidosis Treatment Market Volume (K Unit) Forecast, by Application 2020 & 2033
- Table 39: United Kingdom Transthyretin Amyloidosis Treatment Market Revenue (Million) Forecast, by Application 2020 & 2033
- Table 40: United Kingdom Transthyretin Amyloidosis Treatment Market Volume (K Unit) Forecast, by Application 2020 & 2033
- Table 41: France Transthyretin Amyloidosis Treatment Market Revenue (Million) Forecast, by Application 2020 & 2033
- Table 42: France Transthyretin Amyloidosis Treatment Market Volume (K Unit) Forecast, by Application 2020 & 2033
- Table 43: Italy Transthyretin Amyloidosis Treatment Market Revenue (Million) Forecast, by Application 2020 & 2033
- Table 44: Italy Transthyretin Amyloidosis Treatment Market Volume (K Unit) Forecast, by Application 2020 & 2033
- Table 45: Spain Transthyretin Amyloidosis Treatment Market Revenue (Million) Forecast, by Application 2020 & 2033
- Table 46: Spain Transthyretin Amyloidosis Treatment Market Volume (K Unit) Forecast, by Application 2020 & 2033
- Table 47: Rest of Europe Transthyretin Amyloidosis Treatment Market Revenue (Million) Forecast, by Application 2020 & 2033
- Table 48: Rest of Europe Transthyretin Amyloidosis Treatment Market Volume (K Unit) Forecast, by Application 2020 & 2033
- Table 49: Global Transthyretin Amyloidosis Treatment Market Revenue Million Forecast, by Type 2020 & 2033
- Table 50: Global Transthyretin Amyloidosis Treatment Market Volume K Unit Forecast, by Type 2020 & 2033
- Table 51: Global Transthyretin Amyloidosis Treatment Market Revenue Million Forecast, by Therapy 2020 & 2033
- Table 52: Global Transthyretin Amyloidosis Treatment Market Volume K Unit Forecast, by Therapy 2020 & 2033
- Table 53: Global Transthyretin Amyloidosis Treatment Market Revenue Million Forecast, by Disease Type 2020 & 2033
- Table 54: Global Transthyretin Amyloidosis Treatment Market Volume K Unit Forecast, by Disease Type 2020 & 2033
- Table 55: Global Transthyretin Amyloidosis Treatment Market Revenue Million Forecast, by Distribution Channel 2020 & 2033
- Table 56: Global Transthyretin Amyloidosis Treatment Market Volume K Unit Forecast, by Distribution Channel 2020 & 2033
- Table 57: Global Transthyretin Amyloidosis Treatment Market Revenue Million Forecast, by Country 2020 & 2033
- Table 58: Global Transthyretin Amyloidosis Treatment Market Volume K Unit Forecast, by Country 2020 & 2033
- Table 59: China Transthyretin Amyloidosis Treatment Market Revenue (Million) Forecast, by Application 2020 & 2033
- Table 60: China Transthyretin Amyloidosis Treatment Market Volume (K Unit) Forecast, by Application 2020 & 2033
- Table 61: Japan Transthyretin Amyloidosis Treatment Market Revenue (Million) Forecast, by Application 2020 & 2033
- Table 62: Japan Transthyretin Amyloidosis Treatment Market Volume (K Unit) Forecast, by Application 2020 & 2033
- Table 63: India Transthyretin Amyloidosis Treatment Market Revenue (Million) Forecast, by Application 2020 & 2033
- Table 64: India Transthyretin Amyloidosis Treatment Market Volume (K Unit) Forecast, by Application 2020 & 2033
- Table 65: Australia Transthyretin Amyloidosis Treatment Market Revenue (Million) Forecast, by Application 2020 & 2033
- Table 66: Australia Transthyretin Amyloidosis Treatment Market Volume (K Unit) Forecast, by Application 2020 & 2033
- Table 67: South Korea Transthyretin Amyloidosis Treatment Market Revenue (Million) Forecast, by Application 2020 & 2033
- Table 68: South Korea Transthyretin Amyloidosis Treatment Market Volume (K Unit) Forecast, by Application 2020 & 2033
- Table 69: Rest of Asia Pacific Transthyretin Amyloidosis Treatment Market Revenue (Million) Forecast, by Application 2020 & 2033
- Table 70: Rest of Asia Pacific Transthyretin Amyloidosis Treatment Market Volume (K Unit) Forecast, by Application 2020 & 2033
- Table 71: Global Transthyretin Amyloidosis Treatment Market Revenue Million Forecast, by Type 2020 & 2033
- Table 72: Global Transthyretin Amyloidosis Treatment Market Volume K Unit Forecast, by Type 2020 & 2033
- Table 73: Global Transthyretin Amyloidosis Treatment Market Revenue Million Forecast, by Therapy 2020 & 2033
- Table 74: Global Transthyretin Amyloidosis Treatment Market Volume K Unit Forecast, by Therapy 2020 & 2033
- Table 75: Global Transthyretin Amyloidosis Treatment Market Revenue Million Forecast, by Disease Type 2020 & 2033
- Table 76: Global Transthyretin Amyloidosis Treatment Market Volume K Unit Forecast, by Disease Type 2020 & 2033
- Table 77: Global Transthyretin Amyloidosis Treatment Market Revenue Million Forecast, by Distribution Channel 2020 & 2033
- Table 78: Global Transthyretin Amyloidosis Treatment Market Volume K Unit Forecast, by Distribution Channel 2020 & 2033
- Table 79: Global Transthyretin Amyloidosis Treatment Market Revenue Million Forecast, by Country 2020 & 2033
- Table 80: Global Transthyretin Amyloidosis Treatment Market Volume K Unit Forecast, by Country 2020 & 2033
Frequently Asked Questions
1. What is the projected Compound Annual Growth Rate (CAGR) of the Transthyretin Amyloidosis Treatment Market?
The projected CAGR is approximately 15.40%.
2. Which companies are prominent players in the Transthyretin Amyloidosis Treatment Market?
Key companies in the market include Pfizer Inc, Prothena, SOM BIOTECH, Takeda Pharmaceutical Company Limited, BridgeBio Inc, Millennium Pharmaceuticals, Alnylam Pharmaceuticals Inc, Ionis Pharmaceuticals, Oncopeptides, Corino Therapeutics Inc, Alexion Pharmaceuticals, Intellia Therapeutics Inc.
3. What are the main segments of the Transthyretin Amyloidosis Treatment Market?
The market segments include Type, Therapy, Disease Type, Distribution Channel.
4. Can you provide details about the market size?
The market size is estimated to be USD 5.30 Million as of 2022.
5. What are some drivers contributing to market growth?
Growing Geriatric Population and Risk Factors for Amyloid Light Chain (AL); Increasing Research and Development (R&D) and Growing Disease Awareness.
6. What are the notable trends driving market growth?
The Hereditary Transthyretin Amyloidosis Segment is Expected to Hold a Significant Share Over the Forecast Period.
7. Are there any restraints impacting market growth?
High Cost Associated with the Transthyretin Amyloidosis Treatment.
8. Can you provide examples of recent developments in the market?
April 2024: Alexion, a collaboration partner of Neurimmune and AstraZeneca’s Rare Disease group, initiated the Phase 3 DepleTTR-CM clinical study to assess the efficacy and safety of ALXN2220 for the treatment of transthyretin-mediated amyloid cardiomyopathy (ATTR-CM).
9. What pricing options are available for accessing the report?
Pricing options include single-user, multi-user, and enterprise licenses priced at USD 4750, USD 5250, and USD 8750 respectively.
10. Is the market size provided in terms of value or volume?
The market size is provided in terms of value, measured in Million and volume, measured in K Unit.
11. Are there any specific market keywords associated with the report?
Yes, the market keyword associated with the report is "Transthyretin Amyloidosis Treatment Market," which aids in identifying and referencing the specific market segment covered.
12. How do I determine which pricing option suits my needs best?
The pricing options vary based on user requirements and access needs. Individual users may opt for single-user licenses, while businesses requiring broader access may choose multi-user or enterprise licenses for cost-effective access to the report.
13. Are there any additional resources or data provided in the Transthyretin Amyloidosis Treatment Market report?
While the report offers comprehensive insights, it's advisable to review the specific contents or supplementary materials provided to ascertain if additional resources or data are available.
14. How can I stay updated on further developments or reports in the Transthyretin Amyloidosis Treatment Market?
To stay informed about further developments, trends, and reports in the Transthyretin Amyloidosis Treatment Market, consider subscribing to industry newsletters, following relevant companies and organizations, or regularly checking reputable industry news sources and publications.
Methodology
Step 1 - Identification of Relevant Samples Size from Population Database
Step 2 - Approaches for Defining Global Market Size (Value, Volume* & Price*)
Note*: In applicable scenarios
Step 3 - Data Sources
Primary Research
- Web Analytics
- Survey Reports
- Research Institute
- Latest Research Reports
- Opinion Leaders
Secondary Research
- Annual Reports
- White Paper
- Latest Press Release
- Industry Association
- Paid Database
- Investor Presentations
Step 4 - Data Triangulation
Involves using different sources of information in order to increase the validity of a study
These sources are likely to be stakeholders in a program - participants, other researchers, program staff, other community members, and so on.
Then we put all data in single framework & apply various statistical tools to find out the dynamic on the market.
During the analysis stage, feedback from the stakeholder groups would be compared to determine areas of agreement as well as areas of divergence